智通财经网·2026-03-18 02:19Core Viewpoint - Rongchang Biologics (09995) has seen a significant stock increase, attributed to positive developments in the treatment of urothelial carcinoma and strong financial performance [1] Group 1: Stock Performance - Rongchang Biologics' stock rose nearly 8%, with a current price of 96.8 HKD and a trading volume of 238 million HKD [1] Group 2: Industry Developments - The 2026 European Association of Urology (EAU) annual meeting is taking place in London from March 13 to 16, showcasing innovative applications of HER2-targeted antibody-drug conjugate (ADC) Vidisizumab in urothelial carcinoma treatment [1] - Multiple cutting-edge research results from China are being presented, covering the entire disease spectrum from early to late stages and from bladder cancer to upper urinary tract urothelial carcinoma, providing strong new evidence for precision and organ-preserving treatments [1] Group 3: Financial Performance - Rongchang Biologics recently released a performance report indicating a revenue of 3.251 billion RMB, a year-on-year increase of 89.36% [1] - The company reported a net profit attributable to shareholders of 709 million RMB, marking a turnaround from losses [1] - Revenue growth is primarily driven by increased sales of injectable Taitasip and Vidisizumab, along with significant technology licensing income from granting Vor Biopharma Inc. exclusive global development and commercialization rights for Taitasip outside Greater China [1]